United States Pharmaceuticals

Emergent BioSolutions Inc (EBS)

Track

Over the past 90 days, Emergent BioSolutions Inc. has seen exclusively insider selling activity, totaling approximately $50,405 in value. These transactions, primarily planned or proposed sales by executives and directors, occurred following the company's April 2026 earnings report. The stock has experienced a 15.5% decline over the same period, currently trading near its 52-week low.
Ticker: EBS Exchange: NYS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Emergent BioSolutions Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Planned sale 1 Jul 2026
Value US$4,276,600.74 | Price 115.73 | Shares 62,181 (+0.0%)
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-07-02 2026-07-01 PlS Planned sale
Williams Paul Anthony

SVP, Products Business

Officer
62,181 +0.0%
115.73
US$4,276,601 		62,181 +0.0% 115.73 US$4,276,601
2026-07-01 2026-07-01 PrS Proposed sale
PAUL WILLIAMS

Officer

Officer
21,775
74.42
US$1,204,423 		21,775 74.42 US$1,204,423
2026-05-04 2026-05-01 PlS Planned sale
Dayal Sujata Tyagi
Non-Executive Director
29,258 +24.5%
128.64
US$1,556,427 		29,258 +24.5% 128.64 US$1,556,427
2026-05-04 2026-05-01 PlS Planned sale
Dayal Sujata Tyagi
Non-Executive Director
12,781 -11.2%
8.36
US$106,849 		12,781 -11.2% 8.36 US$106,849
2026-05-04 2026-05-01 PlS Planned sale
3.2
DeGolyer Donald W
Non-Executive Director
954 -0.7%
8.96
US$8,548 		954 -0.7% 8.96 US$8,548
2026-05-04 2026-05-01 PlS Planned sale
3.2
DeGolyer Donald W
Non-Executive Director
14,527 -10.0%
8.36
US$121,446 		14,527 -10.0% 8.36 US$121,446
2026-05-04 2026-05-01 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
1,057 -1.3%
8.97
US$9,481 		1,057 -1.3% 8.97 US$9,481
2026-05-04 2026-05-01 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
16,145 -16.6%
8.36
US$134,972 		16,145 -16.6% 8.36 US$134,972
2026-05-01 2026-05-01 PrS Proposed sale
3.2
DONALD DEGOLYER

Director

Non-Executive Director
15,481
8.40
US$130,064 		15,481 8.40 US$130,064
2026-05-01 2026-05-01 PrS Proposed sale
SUJATA TYAGI DAYAL

Director

Non-Executive Director
13,761
8.40
US$115,612 		13,761 8.40 US$115,612
2026-05-01 2026-05-01 PrS Proposed sale
3.0
KATHRYN ZOON

Director

Non-Executive Director
17,202
8.40
US$144,492 		17,202 8.40 US$144,492
2026-05-04 2026-04-30 PlS Planned sale
3.2
Katkin Keith
Non-Executive Director
15,481 -13.9%
8.28
US$128,183 		15,481 -13.9% 8.28 US$128,183
2026-04-30 2026-04-30 PrS Proposed sale
3.2
KEITH KATKIN

Director

Non-Executive Director
15,481
8.28
US$128,141 		15,481 8.28 US$128,141
2026-04-03 2026-04-01 PlS Planned sale
Williams Paul Anthony

SVP, Products Business

Officer
4,000 -6.0%
8.44
US$33,760 		4,000 -6.0% 8.44 US$33,760
2026-04-03 2026-04-01 PlS Planned sale
Williams Paul Anthony

SVP, Products Business

Officer
4,000 -6.0%
8.44
US$33,760 		4,000 -6.0% 8.44 US$33,760
2026-04-01 2026-04-01 PrS Proposed sale
PAUL WILLIAMS

Officer

Officer
4,000
8.44
US$33,778 		4,000 8.44 US$33,778
2026-01-07 2026-01-07 PrS Proposed sale
3.6
LOUIS W SULLIVAN

Director

Non-Executive Director
25,748
13.99
US$360,142 		25,748 13.99 US$360,142
2025-12-22 2025-12-22 PrS Proposed sale
3.6
LOUIS W SULLIVAN

Director

Non-Executive Director
104,695
12.77
US$1,336,463 		104,695 12.77 US$1,336,463
2025-12-09 2025-12-05 S Sale
2.9
Richard Ronald
Non-Executive Director
14,884 -13.1%
11.90
US$177,087 		14,884 -13.1% 11.90 US$177,087
2025-12-09 2025-12-05 S Sale
2.9
Richard Ronald
Non-Executive Director
7,100 -6.7%
12.11
US$85,990 		7,100 -6.7% 12.11 US$85,990
2025-12-05 2025-12-05 PrS Proposed sale
2.9
RONALD RICHARD

Director

Non-Executive Director
32,848
11.94
US$392,335 		32,848 11.94 US$392,335
2025-11-12 2025-11-10 PlS Planned sale
3.2
DeGolyer Donald W
Non-Executive Director
17,801 -12.9%
10.54
US$187,623 		17,801 -12.9% 10.54 US$187,623
2025-11-10 2025-11-10 PrS Proposed sale
3.2
DONALD DEGOLYER

Director

Non-Executive Director
17,801
10.54
US$187,544 		17,801 10.54 US$187,544
2025-11-10 2025-11-07 PlS Planned sale
Dayal Sujata Tyagi
Non-Executive Director
8,552 -8.8%
10.00
US$85,520 		8,552 -8.8% 10.00 US$85,520
2025-11-07 2025-11-07 PrS Proposed sale
SUJATA TYAGI DAYAL

Director

Non-Executive Director
8,552
10.00
US$85,520 		8,552 10.00 US$85,520
2025-10-16 2025-10-07 PlS Planned sale
Glessner Coleen

EVP, Quality & Ethics, and CPL

Officer
30,608 -17.5%
10.00
US$306,080 		30,608 -17.5% 10.00 US$306,080
2025-10-07 2025-10-07 PrS Proposed sale
COLEEN GLESSNER

Officer

Officer
30,608
10.00
US$306,080 		30,608 10.00 US$306,080
2025-08-18 2025-08-15 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
7,086 -9.0%
8.87
US$62,853 		7,086 -9.0% 8.87 US$62,853
2025-08-15 2025-08-15 PrS Proposed sale
3.0
KATHRYN ZOON

Director

Non-Executive Director
7,086
8.87
US$62,853 		7,086 8.87 US$62,853
2025-08-13 2025-08-12 S Sale
3.2
DeGolyer Donald W
Non-Executive Director
7,844 -5.4%
8.65
US$67,831 		7,844 -5.4% 8.65 US$67,831
2025-08-12 2025-08-12 PrS Proposed sale
3.2
DONALD DEGOLYER

Director

Non-Executive Director
7,844
8.65
US$67,831 		7,844 8.65 US$67,831
2025-05-28 2025-05-23 PlS Planned sale
3.2
Katkin Keith
Non-Executive Director
7,844 -8.3%
6.30
US$49,417 		7,844 -8.3% 6.30 US$49,417
2025-05-23 2025-05-23 PrS Proposed sale
3.2
KEITH KATKIN

Director

Non-Executive Director
7,844
6.30
US$49,409 		7,844 6.30 US$49,409
2025-05-15 2025-05-13 B Purchase
3.1
PAPA JOSEPH C

President and CEO

Executive Director
60,000 +21.2%
5.83
US$349,800 		60,000 +21.2% 5.83 US$349,800
2025-03-12 2025-03-12 PrS Proposed sale
1.5
Fowler Neal Franklin

Director

Non-Executive Director
35,000
5.83
US$204,005 		35,000 5.83 US$204,005
2025-03-12 2025-03-12 PrS Proposed sale
3.0
Zoon Kathryn C

Director

Non-Executive Director
10,000
5.73
US$57,300 		10,000 5.73 US$57,300
2025-03-12 2025-03-12 S Sale
3.0
Zoon Kathryn C
Non-Executive Director
10,000 -18.4%
5.73
US$57,300 		10,000 -18.4% 5.73 US$57,300
2025-03-12 2025-03-12 S Sale
1.5
Fowler Neal Franklin
Non-Executive Director
35,000 -25.7%
5.83
US$204,050 		35,000 -25.7% 5.83 US$204,050
2024-11-14 2024-11-12 S Sale
3.2
DeGolyer Donald W
Non-Executive Director
25,000 -18.4%
10.91
US$272,750 		25,000 -18.4% 10.91 US$272,750
2024-11-12 2024-11-12 PrS Proposed sale
3.2
DeGolyer Donald W

Director

Non-Executive Director
25,000
11.77
US$294,250 		25,000 11.77 US$294,250
2024-11-13 2024-11-11 S Sale
2.7
White Marvin L
Non-Executive Director
14,287 -20.9%
11.97
US$171,015 		14,287 -20.9% 11.97 US$171,015
2024-11-12 2024-11-11 PrS Proposed sale
2.7
White Marvin L

Director

Non-Executive Director
14,287
11.77
US$168,158 		14,287 11.77 US$168,158
2024-06-06 2024-06-04 S Sale
3.0
Zoon Kathryn C
Non-Executive Director
10,000 -15.5%
6.11
US$61,100 		10,000 -15.5% 6.11 US$61,100
2024-06-04 2024-06-04 PrS Proposed sale
3.0
Zoon Kathryn C

Director

Non-Executive Director
10,000
6.11
US$61,100 		10,000 6.11 US$61,100
2024-05-31 2024-05-29 S Sale
3.0
Zoon Kathryn C
Non-Executive Director
1,830 -2.8%
4.61
US$8,436 		1,830 -2.8% 4.61 US$8,436
2024-05-23 2024-05-21 S Sale
3.0
Zoon Kathryn C
Non-Executive Director
1,089 -2.2%
5.78
US$6,294 		1,089 -2.2% 5.78 US$6,294
2023-07-24 2023-06-02 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
1,830 -3.5%
8.35
US$15,280 		1,830 -3.5% 8.35 US$15,280
2023-07-24 2023-05-25 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
1,700 -3.2%
8.38
US$14,246 		1,700 -3.2% 8.38 US$14,246
2022-11-29 2022-11-25 S Sale
2.9
Richard Ronald
Non-Executive Director
1,912 -8.8%
11.94
US$22,829 		1,912 -8.8% 11.94 US$22,829
2022-06-13 2022-06-09 S Sale
3.0
Zoon Kathryn C
Non-Executive Director
1,173 -5.6%
31.52
US$36,973 		1,173 -5.6% 31.52 US$36,973
2022-05-25 2022-05-24 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
1,996 -13.9%
35.53
US$70,918 		1,996 -13.9% 35.53 US$70,918
2021-11-15 2021-11-15 B Purchase
3.0
LINDAHL RICHARD S

EVP, Chief Financial Officer

Officer
3,000 +8.1%
37.46
US$112,380 		3,000 +8.1% 37.46 US$112,380
2021-05-27 2021-05-25 PlS Planned sale
3.0
Zoon Kathryn C
Non-Executive Director
3,139 -17.9%
56.48
US$177,291 		3,139 -17.9% 56.48 US$177,291
2021-03-08 2021-03-04 S Sale
3.6
Bailey Sue
Non-Executive Director
8,168 -25.1%
92.37
US$754,478 		8,168 -25.1% 92.37 US$754,478
2021-03-03 2021-03-01 PlS Planned sale
Havey Adam

EVP, Business Operations

Officer
20,145 -34.5%
99.02
US$1,994,758 		20,145 -34.5% 99.02 US$1,994,758
2021-03-03 2021-03-01 PlS Planned sale
Havey Adam

EVP, Business Operations

Officer
17,134 -31.0%
99.62
US$1,706,889 		17,134 -31.0% 99.62 US$1,706,889
2021-02-09 2021-02-08 PlS Planned sale
2.3
Kramer Robert

President and CEO

Executive Director
13,000 -8.5%
120.03
US$1,560,390 		13,000 -8.5% 120.03 US$1,560,390
2021-02-09 2021-02-08 PlS Planned sale
2.3
Kramer Robert

President and CEO

Executive Director
32,397 -18.9%
120.03
US$3,888,612 		32,397 -18.9% 120.03 US$3,888,612
2021-01-22 2021-01-21 PlS Planned sale
2.3
Kramer Robert

President and CEO

Executive Director
21,900 -13.6%
110.03
US$2,409,657 		21,900 -13.6% 110.03 US$2,409,657
2021-01-22 2021-01-20 PlS Planned sale
2.3
Kramer Robert

President and CEO

Executive Director
2,232 -1.6%
110.00
US$245,520 		2,232 -1.6% 110.00 US$245,520
2021-01-19 2021-01-15 PlS Planned sale
2.3
Kramer Robert

President and CEO

Executive Director
19,026 -12.0%
106.01
US$2,016,901 		19,026 -12.0% 106.01 US$2,016,901
2020-11-12 2020-11-10 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
19,391 -1.7%
88.21
US$1,710,480 		19,391 -1.7% 88.21 US$1,710,480
2020-11-12 2020-11-09 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
20,000 -1.7%
95.26
US$1,905,200 		20,000 -1.7% 95.26 US$1,905,200
2020-11-04 2020-11-03 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director
20,000 -1.7%
90.74
US$1,814,800 		20,000 -1.7% 90.74 US$1,814,800
2020-11-04 2020-11-02 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director
20,000 -1.7%
90.44
US$1,808,800 		20,000 -1.7% 90.44 US$1,808,800
2020-09-25 2020-09-24 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
12,535 -1.1%
98.85
US$1,239,085 		12,535 -1.1% 98.85 US$1,239,085
2020-09-25 2020-09-23 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
13,000 -1.1%
100.58
US$1,307,540 		13,000 -1.1% 100.58 US$1,307,540
2020-09-18 2020-09-17 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
20,000 -1.7%
100.68
US$2,013,600 		20,000 -1.7% 100.68 US$2,013,600
2020-09-18 2020-09-16 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
20,000 -1.7%
102.48
US$2,049,600 		20,000 -1.7% 102.48 US$2,049,600
2020-09-11 2020-09-10 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
20,000 -1.7%
102.66
US$2,053,200 		20,000 -1.7% 102.66 US$2,053,200
2020-09-11 2020-09-09 PlS Planned sale
2.0
El-Hibri Fuad

Chairman

Executive Director Large shareholder
20,000 -1.6%
102.80
US$2,056,000 		20,000 -1.6% 102.80 US$2,056,000
2020-09-04 2020-09-02 S Sale
3.6
SULLIVAN LOUIS W
Non-Executive Director
7,893 -15.6%
111.23
US$877,904 		7,893 -15.6% 111.23 US$877,904
2020-09-04 2020-09-02 S Sale
3.6
SULLIVAN LOUIS W
Non-Executive Director
20,525 -32.4%
111.22
US$2,282,702 		20,525 -32.4% 111.22 US$2,282,702
2020-08-19 2020-08-18 S Sale
3.6
Bailey Sue
Non-Executive Director
4,665 -12.5%
128.31
US$598,564 		4,665 -12.5% 128.31 US$598,564
2020-08-18 2020-08-17 S Sale
3.1
Harsanyi Zsolt
Non-Executive Director
6,609 -21.2%
133.71
US$883,664 		6,609 -21.2% 133.71 US$883,664
Explore more

More insider trading research around Emergent BioSolutions Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America